C.L. Adams, J.L. Short, and A.J. Lawrence Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors Br. J. Pharmacol 159 3 2010 534 542
S. Arai, K. Takuma, H. Mizoguchi, D. Ibi, T. Nagai, K. Takahashi, and et al. Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen Neuropsychopharmacology 33 13 2008 3164 3175
S. Arai, K. Takuma, H. Mizoguchi, D. Ibi, T. Nagai, H. Kamei, and et al. GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice Eur. J. Pharmacol 602 1 2009 101 104
J. Bockaert, J. Pin, and L. Fagni Metabotropic glutamate receptors: an original family of G protein-coupled receptors Fundam. Clin. Pharmacol 7 9 1993 473 485
H. Bräuner-Osborne, and P. Krogsgaard-Larsen Functional pharmacology of cloned heterodimeric GABAB receptors expressed in mammalian cells Br. J. Pharmacol 128 7 1999 1370 1374
D. Bugarski-Kirola, Wang A., D. Abi-Saab, and T. Blättler A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study Eur. Neuropsychopharmacol 24 7 2014 1024 1036
M. Cannella, M. Motolese, D. Bucci, G. Molinaro, R. Gradini, V. Bruno, and et al. Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced Parkinsonism Neuropharmacology 95 2015 50 58
Chen Y., N. Menendez-Roche, and E. Sher Differential modulation by the GABAB receptor allosteric potentiator 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930) of synaptic transmission in the rat hippocampal CA1 area J. Pharmacol. Exp. Ther 317 3 2006 1170 1177
B. Chruścicka, G. Burnat, P. Brański, P. Chorobik, T. Lenda, M. Marciniak, and et al. Tetracycline-based system for controlled inducible expression of group III metabotropic glutamate receptors J. Biomol. Screen 20 3 2015 350 358
P.J. Conn, C.K. Jones, and C.W. Lindsley Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci 30 3 2009 148 155
R. Corbett, Zhou L., S.M. Sorensen, and C. Mondadori Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice Neuropsychopharmacology 21 1999 S211 S218
M.T. Craig, E.W. Mayne, B. Bettler, O. Paulsen, and C.J. McBain Distinct roles of GABAB1a- and GABAB1b-containing GABAB receptors in spontaneous and evoked termination of persistent cortical activity J. Physiol 591 Pt 4 2013 835 843
J.F. Cryan, P.H. Kelly, F. Chaperon, C. Gentsch, C. Mombereau, K. Lingenhoehl, and et al. Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines J. Pharmacol. Exp. Ther 310 3 2004 952 963
J.M. Darrah, M.R. Stefani, and B. Moghaddam Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm Behav. Pharmacol 19 3 2008 225 234
E. Dere, J.P. Huston, and M.A. De Souza Silva The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents Neurosci. Biobehav. Rev 31 5 2012 673 704
S.H. Fatemi, T.J. Reutiman, and T.D. Folsom Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats Schizophr. Res 111 1-3 2009 138 152
M.J. Fell, D.L. McKinzie, J.A. Monn, and K.A. Svensson Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia Neuropharmacology 62 3 2012 1473 1483
P.J. Flor, and F.C. Acher Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs Biochem. Pharmacol 84 4 2012 414 424
R. Frau, V. Bini, G. Pillolla, P. Malherbe, A. Pardu, A.W. Thomas, and et al. Positive allosteric modulation of GABAB receptors ameliorates sensorimotor gating in rodent models CNS Neurosci. Ther 20 7 2014 679 684 10.1111/cns.12261
K. Fuxe, D.O. Borroto-Escuela, D. Marcellino, W. Romero-Fernandez, M. Frankowska, D. Guidolin, and et al. GPCR heteromers and their allosteric receptor-receptor interactions Curr. Med. Chem 19 3 2012 356 363
F. Gastambide, M.C. Cotel, G. Gilmour, M.J. O'Neill, T.W. Robbins, and M.D. Tricklebank Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator Neuropsychopharmacology 37 4 2012 1057 1066
A. Guidotti, J. Auta, J.M. Davis, V. Di-Giorgi-Gerevini, Y. Dwivedi, D.R. Grayson, and et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study Arch. Gen. Psychiatry 57 11 2000 1061 1069
M. Hirono, T. Yoshioka, and S. Konishi GABA(B) receptor activation enhances mGluR-mediated responses at cerebellar excitatory synapses Nat. Neurosci 4 12 2001 1207 1216
M. Horiguchi, Huang M., and H.Y. Meltzer Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats Psychopharmacology (Berl) 217 1 2011 13 24
M. Horiguchi, Huang M., and H.Y. Meltzer The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats J. Pharmacol. Exp. Ther 338 2 2011 605 614
M. Horio, Y. Fujita, and K. Hashimoto Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice Fundam. Clin. Pharmacol 27 5 2013 483 488
D.C. Javitt Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia Hillside J. Clin. Psychiatry 9 1 1987 12 35
D.C. Javitt Glutamatergic theories of schizophrenia Isr. J. Psychiatry Relat. Sci 47 1 2010 4 16
E. Jung, M. Wiesjahn, and T.M. Lincoln Negative, not positive symptoms predict the early therapeutic alliance in cognitive behavioral therapy for psychosis Psychother. Res 24 2 2014 171 183
K. Kanuma, T. Aoki, and Y. Shimazaki Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia Recent Pat. CNS Drug Discov 5 1 2010 23 34
G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, and M.K. Clements A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther 313 1 2005 199 206
B.J. Kinon, Zhang L., B.A. Millen, O.O. Osuntokun, J.E. Williams, S. Kollack-Walker, and et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia J. Clin. Psychopharmacol 31 3 2011 349 355
B. Langen, R. Dost, U. Egerland, H. Stange, and N. Hoefgen Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test Psychopharmacology (Berl) 221 2 2012 249 259
C.W. Lindsley, D.D. Wisnoski, W.H. Leister, J.A. O'brien, W. Lemaire, D.L. Williams Jr., and et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo J. Med. Chem 47 24 2004 5825 5828
Liu F., S. Grauer, C. Kelley, R. Navarra, R. Graf, and Zhang G. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther 327 3 2008 827 839
H.Y. Meltzer Update on typical and atypical antipsychotic drugs Annu. Rev. Med 64 2013 393 406
H. Mizoguchi, and K. Yamada Pharmacologic treatment with GABA(B) receptor agonist of methamphetamine-induced cognitive impairment in mice Curr. Neuropharmacol 9 1 2011 109 112
C. Mombereau, L. Lhuillier, K. Kaupmann, and J.F. Cryan GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation J. Pharmacol. Exp. Ther 321 1 2007 172 177
Y. Noda, K. Yamada, H. Furukawa, and T. Nabeshima Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia Br. J. Pharmacol 116 5 1995 2531 2537
Y. Noda, T. Mamiya, H. Furukawa, and T. Nabeshima Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice Eur. J. Pharmacol 324 2-3 1997 135 140
Y. Noda, H. Kamei, T. Mamiya, H. Furukawa, and T. Nabeshima Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions Neuropsychopharmacology 23(4) 2000 375 387
K. Ossowska, J. Konieczny, S. Wolfarth, and A. Pilc MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats Neuropharmacology 49 4 2005 447 455
K. Ossowska, J. Konieczny, J. Wardas, M. Pietraszek, K. Kuter, S. Wolfarth, and et al. An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats Amino Acids 32 2 2006 179 188
A. Pałucha-Poniewiera, and A. Pilc Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test Prog. Neuropsychopharmacol Biol. Psychiatry 39 1 2012 102 106
A. Pałucha-Poniewiera, A. Kłodzińska, K. Stachowicz, K. Tokarski, G. Hess, S. Schann, and et al. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents Neuropharmacology 55 4 2008 517 524
S. Parmentier-Batteur, P.H. Hutson, K. Menzel, J.M. Uslaner, B.A. Mattson, J.A. O'Brien, and et al. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators - development challenges for a promising novel antipsychotic target Neuropharmacology 82 2014 161 173
A. Pilc, P. Brański, A. Pałucha, K. Tokarski, and M. Bijak Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region Eur. J. Pharmacol 349 1 1998 83 87
C.M. Reichel, M. Schwendt, J.F. McGinty, M.F. Olive, and R.E. See Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5 Neuropsychopharmacology 36 4 2011 782 792
M.L. Rives, C. Vol, Y. Fukazawa, N. Tinel, E. Trinquet, M.A. Ayoub, and et al. Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration EMBO J. 28 15 2009 2195 2208
A.L. Rodriguez, M.D. Grier, C.K. Jones, E.J. Herman, A.S. Kane, and R.L. Smith Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol 78 6 2010 1105 1123
D.H. Rominger, C.L. Cowan, W. Gowen-MacDonald, and J.D. Violin Biased ligands: pathway validation for novel GPCR therapeutics Curr. Opin. Pharmacol 16C 2014 108 115
J.M. Rook, M.J. Noetzel, W.A. Pouliot, T.M. Bridges, P.N. Vinson, H.P. Cho, and et al. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity Biol. Psychiatry 73 6 2013 501 509
W. Rössler, H.J. Salize, J. van Os, and A. Riecher-Rössler Size of burden of schizophrenia and psychotic disorders Eur. Neuropsychopharmacol 15 4 2005 399 409
B. Sadzot, J.M. Baraban, R.A. Glennon, R.A. Lyon, S. Leonhardt, C.R. Jan, and et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis Psychopharmacology (Berl) 98 4 1989 495 499
A. Satow, G. Suzuki, S. Maehara, H. Hikichi, T. Murai, T. Murai, and et al. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one J. Pharmacol. Exp. Ther 330 1 2009 179 190
J.L. Scruggs, D. Schmidt, and A.Y. Deutch The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats Neurosci. Lett 346 3 2003 137 140
J.A. Siuciak, D.S. Chapin, S.A. McCarthy, and A.N. Martin Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme Psychopharmacology (Berl) 192 3 2007 415 424
D.A. Slattery, A. Markou, W. Froestl, and J.F. Cryan The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat Neuropsychopharmacology 30 11 2005 2065 2072
A. Sławińska, J.M. Wierońska, K. Stachowicz, M. Marciniak, M. Lasoń-Tyburkiewicz, P. Gruca, and et al. The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents Br. J. Pharmacol 169 8 2013 1824 1839
N. Spear, R.A. Gadient, D.E. Wilkins, M. Do, J.S. Smith, and K.L. Zeller Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator Eur. J. Pharmacol 659 2-3 2011 146 154
T. Tabata, and M. Kano GABA(B) receptor-mediated modulation of glutamate signaling in cerebellar Purkinje cells Cerebellum 5 2 2006 127 133
T. Tabata, and M. Kano GABAB receptor-mediated modulation of metabotropic glutamate signaling and synaptic plasticity in central neurons Adv. Pharmacol 58 2010 149 173
Tu J.C., Xiao B., S. Naisbitt, Yuan J.P., R.S. Petralia, P. Brakeman, and et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins Neuron 23 3 1999 583 592
S. Urwyler, J. Mosbacher, K. Lingenhoehl, J. Heid, K. Hofstetter, W. Froestl, and et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501 Mol. Pharmacol 60 5 2001 963 971
S. Urwyler, M.F. Pozza, K. Lingenhoehl, J. Mosbacher, C. Lampert, W. Froestl, and et al. N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function J. Pharmacol. Exp. Ther 307 1 2003 322 330
J.M. Uslaner, S. Parmentier-Batteur, R.B. Flick, N.O. Surles, J.S. Lam, C.H. McNaughton, and et al. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus Neuropharmacology 57 5-6 2009 531 538
J.D. Vardigan, S.L. Huszar, C.H. McNaughton, P.H. Hutson, and J.M. Uslaner MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol. Biochem. Behav 95 2 2010 223 229
J.M. Wierońska, K. Kłak, A. Pałucha, P. Brański, and A. Pilc Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex Brain Res 1184 2007 88 95
J.M. Wierońska, and A. Pilc Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs Neurochem. Int 55 1-3 2009 85 97
J.M. Wierońska, M. Kusek, K. Tokarski, J. Wabno, W. Froestl, and A. Pilc The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice Br. J. Pharmacol 163 5 2011 1034 1047
J.M. Wierońska, K. Stachowicz, F. Acher, T. Lech, and A. Pilc Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia Psychopharmacology (Berl) 220 3 2012 481 494
J.M. Wierońska, F.C. Acher, A. Sławińska, P. Gruca, M. Lasoń-Tyburkiewicz, M. Papp, and et al. The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling Psychopharmacology (Berl) 227 4 2013 711 725
J.M. Wierońska, A. Sławińska, M. Łasoń-Tyburkiewicz, P. Gruca, M. Papp, S.H. Zorn, and et al. The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies Psychopharmacology (Berl) 232 1 2015 259 273
